Eli Lilly to Buy Centessa Pharmaceuticals, Maker of a Narcolepsy Drug, in $6.3B Deal

Eli Lilly is paying $6.3 billion in cash to acquire Centessa Pharmaceuticals and its experimental narcolepsy drug, marking a 38% premium to Monday's close and the latest in a frenzy of pharmaceutical consolidation aimed at capturing specialized neurological franchises before peer competition intensifies [1]. The deal, announced Tuesday alongside Biogen's $5.6 billion purchase of immunology specialist Apellis, underscores how pharma giants are weaponizing M&A to plug pipeline gaps in high-value therapeutic categories where first-mover advantage translates to durable market share [1][2].

The Centessa transaction values the U.K. and Boston-based biotech at $38 per share, representing a 40.5% premium over its 30-day average share price. Contingent value rights could push the total consideration to $47 per share if Centessa's assets secure U.S. regulatory approval, adding another $1.5 billion to the deal and bringing the potential headline figure to $7.8 billion [1].

Lilly's move comes as multiple companies advance competing therapies for narcolepsy and related sleep-wake disorders, a market where treatment options remain limited and patient populations are underserved. The acquisition gives Lilly immediate access to Centessa's lead program, which has emerged from a portfolio that once spanned more than a dozen programs across diverse disease areas when the company launched publicly in 2021 [1].

Why this matters: The transaction illustrates how established pharmaceutical manufacturers are paying steep premiums to acquire clinical-stage assets rather than bearing the risk and time cost of internal development. For institutional capital, the dual announcements signal that specialty pharma M&A valuations have re-expanded despite broader market volatility, with strategic buyers willing to deploy billions for assets years away from commercialization.

Premium Pricing in a Consolidating Landscape

Lilly's willingness to pay a 38% premium for a clinical-stage company reflects the strategic calculus driving pharmaceutical M&A in 2026: scarcity value trumps development risk when the target addresses an unmet medical need in a confined competitive landscape. Centessa's pivot from a multi-program platform to a focused sleep disorder franchise reduced execution risk for acquirers, making it a cleaner strategic fit despite the inherent uncertainty of regulatory approval timelines.

The structure of the deal reveals Lilly's confidence and caution in equal measure. The $38-per-share upfront payment provides Centessa shareholders with immediate liquidity at a substantial premium, while the contingent payments of up to $9 per share additional consideration tie roughly 19% of the total deal value to regulatory milestones. This risk-sharing mechanism has become standard architecture in biopharma M&A, allowing acquirers to hedge against clinical or regulatory setbacks while incentivizing target management to support a smooth transition through approval processes.

Biogen's simultaneous announcement of its $5.6 billion Apellis acquisition provides a useful comparable. Biogen is paying $41 per share for Apellis, more than double that company's closing price on Monday, with additional contingent payments of up to $4 per share tied to sales thresholds for Syfovre, Apellis' approved drug for geographic atrophy secondary to age-related macular degeneration [2]. Apellis reported $587 million in Syfovre sales for 2025, giving investors a revenue benchmark against which to measure the acquisition multiple [2].

The Biogen-Apellis transaction differs structurally from Lilly-Centessa in a critical dimension: Apellis brings two commercial-stage assets, including Syfovre approved in 2023, whereas Centessa's lead program remains in development. Yet both deals command headline valuations above $5 billion, suggesting strategic buyers are indifferent to development stage when the therapeutic rationale and competitive positioning align with corporate priorities.

Following the Money: Premium Multiples and Strategic Rationale

The financial architecture of these transactions reflects a broader industry dynamic. Lilly is deploying capital to acquire a potential franchise in sleep disorders at a moment when its core growth engines face patent cliffs and competitive pressures. The company's ability to pay $6.3 billion upfront in cash signals both balance sheet strength and an urgency to deploy capital before valuations compress further or competitive bidders emerge.

Centessa's 30-day average share price, against which Lilly is paying a 40.5% premium, provides the cleanest measure of pre-deal valuation. That metric strips out single-day volatility and potential deal speculation, offering a benchmark that reflects market consensus on the standalone asset's risk-adjusted value. The premium implies Lilly sees strategic value—whether from accelerated development timelines, commercial synergies, or competitive foreclosure—worth roughly $1.7 billion beyond what public market investors ascribed to Centessa prior to acquisition talks.

The Apellis deal offers a parallel lens. Biogen's offer of $41 per share for a company trading at roughly half that level on Monday underscores how strategic buyers are willing to pay multiples that dwarf public market valuations when acquiring assets in high-priority categories. The Syfovre revenue run rate of $587 million implies Biogen is paying roughly 9.5 times trailing revenue for the Apellis franchise, a multiple that would have been unthinkable in the capital-constrained environment of 2023-2024 but reflects the return of aggressive M&A pricing in specialized therapeutic areas [2].

Sleep Disorders: A Crowded Pipeline and a Narrow Window

Lilly's Centessa acquisition positions the pharmaceutical giant in a competitive race. The source material notes that multiple companies are advancing drugs targeting narcolepsy, though specific competitors and pipeline details were not disclosed [1]. This competitive backdrop likely contributed to Lilly's decision to move decisively with a 38% premium rather than risk losing the asset to a rival bidder or waiting for clinical data that could either inflate the price or eliminate the opportunity.

Narcolepsy and related sleep-wake disorders represent a therapeutic area with limited approved treatment options and significant unmet need. Patients often cycle through multiple therapies seeking adequate symptom control, creating an opportunity for novel mechanisms of action to capture market share even in categories with existing drugs. For Lilly, the strategic value extends beyond the lead asset: acquiring Centessa provides access to the company's sleep disorder expertise, clinical infrastructure, and potential follow-on programs that could generate additional pipeline optionality.

The timing of the acquisition is notable. Centessa publicly launched in 2021 with a broad portfolio strategy spanning more than a dozen programs across multiple diseases. Its subsequent focus on sleep disorders suggests the company identified this as the highest-probability path to value creation—a thesis Lilly is now betting $6.3 billion to validate. The compressed timeline from launch to acquisition reflects how quickly biopharma companies can pivot to capture emerging opportunities when clinical data or competitive dynamics shift.

The Plocamium View

Lilly's Centessa acquisition and Biogen's simultaneous Apellis purchase signal a structural shift in pharmaceutical M&A that institutional investors should monitor closely. The willingness of cash-rich strategic buyers to deploy billions for clinical-stage or recently commercial assets at premium multiples indicates three things: first, internal R&D productivity remains insufficient to meet growth targets, forcing companies to acquire innovation externally; second, the competitive landscape in high-value therapeutic categories has become sufficiently crowded that pre-emptive acquisitions now carry strategic value even at elevated prices; and third, the cost of capital for pharmaceutical acquirers has declined to levels that make large cash deals economically viable despite regulatory and development risk.

The contingent value structure in both deals deserves attention. Lilly's $9-per-share CVR and Biogen's $4-per-share earnout represent 19% and 9% of total deal value respectively, suggesting acquirers are structuring transactions to share regulatory and commercial risk with target shareholders. This marks a departure from the all-cash, full-premium deals of prior cycles and could become the dominant architecture for biopharma M&A as buyers seek downside protection in an environment where FDA approval timelines remain uncertain and commercial execution carries meaningful risk.

The broader implication for institutional portfolios: mid-cap biotech companies with focused franchises in areas of strategic interest to large pharma—oncology, immunology, neurology, rare disease—now trade with embedded acquisition optionality that public market valuations may not fully reflect. The 38% and 100%-plus premiums in these transactions suggest the spread between public market pricing and strategic buyer willingness to pay has widened significantly, creating opportunities for investors who can identify acquisition candidates before deal speculation inflates valuations.

We expect additional transactions in the $5 billion to $10 billion range over the next 12 to 18 months as pharma companies deploy cash ahead of potential tax policy changes and before competitive dynamics in key therapeutic categories solidify. Sleep disorders, immunology, and targeted oncology represent the categories with the highest probability of near-term consolidation based on pipeline density and unmet medical need.

The Bottom Line

Lilly's $6.3 billion bet on Centessa reflects the new economics of pharmaceutical M&A: pay a steep premium now to secure a competitive position in a high-value category, or risk being shut out as the therapeutic landscape consolidates. The simultaneous Biogen-Apellis transaction confirms this is not an isolated event but a systematic repricing of biotech assets by strategic buyers with capital to deploy and pipelines to fill.

For investors, the message is clear: mid-cap biotech companies with de-risked clinical assets in areas of unmet need now trade at valuations that may not capture their strategic acquisition value. The 40% premiums in these deals suggest the gap between public market pricing and strategic buyer willingness to pay remains wide—and that gap represents opportunity for capital positioned to identify the next acquisition target before the market does. Watch for additional transactions in neurology, immunology, and rare disease as pharma companies continue to prioritize external innovation over internal development in the race to capture franchise value before competition forecloses the opportunity.